Skip to main content
Premium Trial:

Request an Annual Quote

Genedrive: James Cheek, Gino Miele, David Budd

James Cheek has been appointed as CEO of UK-based molecular diagnostics firm Genedrive. He is succeeding David Budd, who stepped down as CEO. Cheek previously held positions at Cepheid, Beckman Coulter, and Roche Diagnostics.

In addition, CSO Gino Miele has been appointed as executive director of Genedrive. He was previously R&D director of Genedrive and the company's predecessor Epistem. Prior to that, he held associate director positions in personalized medicine at Wyeth and at Pfizer.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.